Clinical trial · no report yet · Phase 3
MajesTEC-3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05083169 ↗
- Active not recruiting
- Janssen Research & Development, LLC
- 354 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 145 | |
| YouTube | 137 | |
| Podcasts | 64 | |
| X videos | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab; Pomalidomide; Dexamethasone; Bortezomib; Teclistamab
- Arms
- Arm A: Teclistamab-daratumumab (Tec-Dara) · Experimental
- Arm B: DPd or DVd · Experimental
- Enrollment
- 587
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Oct 14, 2021
- Primary completion
- Aug 1, 2025
- Results posted
- No
- Registry record
- NCT05083169 · updated Sep 25, 2026
Publications
linked from the registry- Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV; MajesTEC-3 Trial Investigators. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2026 Feb 19;394(8):739-752. doi: 10.1056/NEJMoa2514663. Epub 2025 Dec 9. PubMed 41363801